Clinical Trial Update: Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation and expansion trial of a SAR444200-based regimen in adults with advanced solid tumors; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• SAR444200 (SAR444200)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm | Phase 1, Phase 2 | Status: TERMINATED